M30-M36

Systemic connective tissue disorders

The ICD-10-CM range M30-M36 encompasses a group of autoimmune and inflammatory conditions characterized by systemic involvement of the connective tissues, which support and bind other tissues and organs. These disorders, often called collagen vascular diseases, typically involve a loss of immune tolerance, leading to the production of autoantibodies and systemic inflammation. The spectrum includes necrotizing vasculopathies (like Polyarteritis nodosa), systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis (Scleroderma), and Sjögren's syndrome. Clinical manifestations are diverse because connective tissue is ubiquitous, often affecting the skin, joints, kidneys, heart, lungs, and nervous system. Management usually requires multidisciplinary care involving rheumatologists and specialists relevant to the affected organ systems, focusing on immunosuppression and symptom control.

Clinical Symptoms

  • Arthralgia and inflammatory arthritis
  • Malar rash (butterfly rash) or other photosensitive skin eruptions
  • Raynaud's phenomenon (digital color changes in response to cold)
  • Proximal muscle weakness (characteristic of myositis)
  • Heliotrope rash (purple discoloration of eyelids)
  • Sicca symptoms (severe dryness of eyes and mouth)
  • Unexplained chronic fatigue and low-grade fever
  • Digital ulcers or pitting scars
  • Sclerodactyly (thickening and tightening of skin on fingers)
  • Pleuritic chest pain or pericarditis
  • Proteinuria or hematuria (indicating renal involvement)
  • Dyspnea or dry cough (indicating interstitial lung disease)

Common Causes

  • Genetic predisposition (specific HLA-DRB1 and HLA-DQ alleles)
  • Loss of immune self-tolerance and production of antinuclear antibodies (ANA)
  • Environmental triggers including ultraviolet (UV) light exposure
  • Infectious triggers such as Epstein-Barr virus (EBV) or Cytomegalovirus (CMV)
  • Hormonal influences, evidenced by high prevalence in females of childbearing age
  • Exposure to crystalline silica or certain organic solvents
  • Drug-induced reactions (e.g., drug-induced lupus)
  • Epigenetic modifications affecting immune cell function

Documentation & Coding Tips

Distinguish between systemic lupus erythematosus and drug-induced lupus to ensure correct code selection and risk adjustment.

Example: Patient with established Systemic Lupus Erythematosus (M32.10) presenting with new-onset glomerulonephritis. Currently on Hydroxychloroquine 400mg daily. Laboratory results show elevated anti-dsDNA and low C3/C4 levels, confirming acute lupus nephritis. Plan: Initiate mycophenolate mofetil and adjust prednisone. Diagnosis updated to M32.14 (Glomerular disease in systemic lupus erythematosus). This supports HCC 40 and reflects a chronic, high-severity condition requiring complex management.

Billing Focus: Identify the specific organ system manifestation such as renal, cardiac, or pulmonary to move from M32.9 to more specific codes like M32.14.

For Systemic Sclerosis, differentiate between diffuse, limited, and drug-induced forms while documenting specific organ involvement like lung or heart.

Example: Patient with Diffuse Systemic Sclerosis (M34.0) experiencing progressive dyspnea. HRCT shows honeycombing consistent with interstitial lung disease. Pulmonary function tests reveal a decline in FVC to 60 percent predicted. Diagnosis: Systemic sclerosis with lung involvement (M34.81). Ongoing management includes Mycophenolate and Nintedanib. This documentation captures the multisystem nature and disease severity.

Billing Focus: Laterality is not typically applicable for systemic connective tissue disorders, but specificity regarding the internal organ affected is mandatory.

Document the specific type of vasculitis and the presence of any secondary manifestations or renal involvement.

Example: Patient with Granulomatosis with polyangiitis (M31.31) presenting with hematuria and elevated creatinine (2.4 mg/dL). Renal biopsy confirmed necrotizing glomerulonephritis. Patient started on Rituximab and high-dose IV methylprednisolone for induction therapy. Documentation of M31.31 (Granulomatosis with polyangiitis with kidney involvement) ensures the highest level of specificity and clinical accuracy.

Billing Focus: Capture the acuity of the condition (e.g., active vasculitis vs. remission) and the specific organ systems involved (renal vs. pulmonary).

When documenting Sjogren Syndrome, specify if it is primary or secondary and list all associated manifestations such as keratoconjunctivitis or lung involvement.

Example: Patient diagnosed with Sjogren Syndrome with keratoconjunctivitis (M35.01). Complains of severe xerostomia and gritty sensation in eyes. Schirmer test positive at 3mm. Prescribed Restasis and Salagen. Evaluated for extraglandular manifestations, currently negative for pulmonary involvement. Documentation supports both the underlying syndrome and the specific ocular complication.

Billing Focus: Use fourth and fifth characters to specify complications such as lung involvement (M35.02) or myopathy (M35.03).

Specify the exact overlap syndrome or undifferentiated connective tissue disease when criteria for a single definitive diagnosis are not met.

Example: Patient presents with features of systemic sclerosis (Raynaud's, sclerodactyly) and polymyositis (proximal muscle weakness, elevated CPK). Anti-U1 RNP antibody is positive. Diagnosis: Mixed Connective Tissue Disease (M35.1). Patient initiated on Prednisone 20mg and Methotrexate. This specific code accurately reflects the multi-disease overlap.

Billing Focus: Ensure code M35.1 is used only when Mixed Connective Tissue Disease is clinically confirmed, as it is distinct from Undifferentiated Connective Tissue Disease (M35.9).

Relevant CPT Codes

Related Diagnoses

Hierarchy